These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30972995)

  • 1. Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus.
    Wang RR; Lv ZM; Dan YP; Chen KY; Zhang C
    J Biol Regul Homeost Agents; 2019; 33(2):365-374. PubMed ID: 30972995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
    Shi CH; Wang L; Bai R; Wang YB; Liu D; Zhang XY; Wang H; Yang Y; Du JL
    Zhonghua Yi Xue Za Zhi; 2016 Aug; 96(32):2554-8. PubMed ID: 27596550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
    Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
    Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improvement in blood glucose fluctuations of insulin-treated type 1 diabetic patients with additional use of acarbose and assessed by continuous blood glucose monitoring program].
    Ma YR; Xu YC; Ge JP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):854-6. PubMed ID: 22967344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus.
    Jin H; Zhang H
    Evid Based Complement Alternat Med; 2022; 2022():3541931. PubMed ID: 35845580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Wan H; Zhao D; Shen J; Lu L; Zhang T; Chen Z
    J Diabetes Res; 2016; 2016():9849328. PubMed ID: 26798658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
    Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ; Yao MY; Ma JX; Xue P; Li YK
    Endocr J; 2019 Oct; 66(10):871-880. PubMed ID: 31243192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hand grip strength is inversely associated with total daily insulin dose requirement in patients with type 2 diabetes mellitus: a cross-sectional study.
    Chen DS; Zhu YQ; Ni WJ; Li YJ; Yin GP; Shao ZY; Zhu J
    PeerJ; 2023; 11():e15761. PubMed ID: 37489121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed-meal tests in drug-naïve type 2 diabetic patients.
    Li H; Xu W; Liu J; Chen A; Liao Z; Li Y
    Biomed Rep; 2013 Nov; 1(6):913-917. PubMed ID: 24649052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
    Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus.
    Wang C; Lv L; Yang Y; Chen D; Liu G; Chen L; Song Y; He L; Li X; Tian H; Jia W; Ran X
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):810-5. PubMed ID: 21854404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mulberry twig alkaloids(Sangzhi alkaloids) and metformin on blood glucose fluctuations in combination with premixed insulin-treated patients with type 2 diabetes.
    Meng Z; Xu C; Liu H; Gao X; Li X; Lin W; Ma X; Yang C; Hao M; Zhao K; Hu Y; Wang Y; Kuang H
    Front Endocrinol (Lausanne); 2023; 14():1272112. PubMed ID: 38027146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring.
    Uemura F; Okada Y; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2018 Feb; 20(2):140-146. PubMed ID: 29293363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.